Sign in
4

Changes in Ownership

Karyopharm Therapeutics Inc. Filed Acc 0001209191-22-011643

EVP, Chief Dev. Officer sold 2,929 shares at $12.12 ($35,509)

From the SEC's structured data for this filing

Trades in this filing

Frenkel Ran · EVP, Chief Dev. Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2022-02-17 Sale : show line 1 in the form −2,929 $12.12 $35,509 101,703 D
Open-market sales · 2,929 sh · avg $12.12 · $35,509
Loading xslF345X03/doc4.xml…